Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Retained Earnings (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Retained Earnings for 17 consecutive years, with -$270.4 million as the latest value for Q1 2026.

  • Quarterly Retained Earnings fell 23.81% to -$270.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$270.4 million through Mar 2026, down 23.81% year-over-year, with the annual reading at -$260.2 million for FY2025, 26.58% down from the prior year.
  • Retained Earnings for Q1 2026 was -$270.4 million at Achieve Life Sciences, down from -$260.2 million in the prior quarter.
  • The five-year high for Retained Earnings was $3000.0 in Q2 2025, with the low at -$270.4 million in Q1 2026.
  • Average Retained Earnings over 5 years is -$167.3 million, with a median of -$165.8 million recorded in 2023.
  • The sharpest move saw Retained Earnings plummeted 47.82% in 2022, then skyrocketed 100.0% in 2025.
  • Achieve Life Sciences' Retained Earnings stood at -$135.9 million in 2022, then decreased by 21.93% to -$165.8 million in 2023, then fell by 24.03% to -$205.6 million in 2024, then fell by 26.58% to -$260.2 million in 2025, then decreased by 3.91% to -$270.4 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Retained Earnings are -$270.4 million (Q1 2026), -$260.2 million (Q4 2025), and -$245.6 million (Q3 2025).